Abstract
The outbreak of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, in December 2019, and its global dissemination became the coronavirus disease 2019 (COVID-19) pandemic declared by the World Health Organization (WHO) on 11 March 2020. In patients undergoing immunotherapy, the effect and path of viral infection remain uncertain. In addition, viral-infected mice and humans show T-cell exhaustion, which is identified after infection with SARS-CoV-2. Notably, they regain their T-cell competence and effectively prevent viral infection when treated with anti-PD-1 antibodies. Four clinical trials are officially open to evaluate anti-PD-1 antibody administration’s effectiveness for cancer and non-cancer individuals influenced by COVID-19 based on these findings. The findings may demonstrate the hypothesis that a winning strategy to combat SARS-CoV-2 infection could be the restoration of exhausted T-cells. In this review, we outline the potential protective function of the anti-PD-1 blockade against SARS-CoV-2 infection with the aim to develop SARS-CoV-2 therapy.
Keywords: Anti-PD-1; COVID-19; Immunotherapy; SARS-CoV-2; T-cells.
【저자키워드】 COVID-19, SARS-CoV-2, Immunotherapy, T-cells, Anti-PD-1, 【초록키워드】 coronavirus disease, severe acute respiratory syndrome coronavirus 2, antibodies, viral infection, Coronavirus disease 2019, coronavirus, clinical trial, pandemic, therapy, antibody, Immunotherapy, SARS-COV-2 infection, Cancer, Human, T-cells, severe acute respiratory syndrome Coronavirus, PD-1, outbreak, mice, Wuhan, Patient, Effectiveness, WHO, T-cell, dissemination, T-cell exhaustion, Protective, Hypothesis, administration, Health Organization, World Health Organization, acute respiratory syndrome, acute respiratory syndrome coronavirus, individual, restoration, blockade, path, Prevent, Wuhan, China, develop, evaluate, addition, treated, infection with SARS-CoV-2, 【제목키워드】 protective role, blockade, Potential,